These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 36159777)
1. TRIM22 orchestrates the proliferation of GBMs and the benefits of TMZ by coordinating the modification and degradation of RIG-I. Fei X; Wu X; Dou YN; Sun K; Guo Q; Zhang L; Li S; Wei J; Huan Y; He X; Fei Z Mol Ther Oncolytics; 2022 Sep; 26():413-428. PubMed ID: 36159777 [TBL] [Abstract][Full Text] [Related]
2. TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα. Ji J; Ding K; Luo T; Zhang X; Chen A; Zhang D; Li G; Thorsen F; Huang B; Li X; Wang J Cell Death Differ; 2021 Jan; 28(1):367-381. PubMed ID: 32814880 [TBL] [Abstract][Full Text] [Related]
3. TRIM22 promotes the proliferation of glioblastoma cells by activating MAPK signaling and accelerating the degradation of Raf-1. Fei X; Dou YN; Sun K; Wei J; Guo Q; Wang L; Wu X; Lv W; Jiang X; Fei Z Exp Mol Med; 2023 Jun; 55(6):1203-1217. PubMed ID: 37258577 [TBL] [Abstract][Full Text] [Related]
4. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
5. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123 [TBL] [Abstract][Full Text] [Related]
6. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. Haemmig S; Baumgartner U; Glück A; Zbinden S; Tschan MP; Kappeler A; Mariani L; Vajtai I; Vassella E Cell Death Dis; 2014 Jun; 5(6):e1279. PubMed ID: 24901050 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of TRIM22 Relieves Oxygen-Glucose Deprivation/Reoxygenation-Induced Apoptosis and Inflammation Through Inhibition of NF-κB/NLRP3 Axis. Kang C; Lu Z; Zhu G; Chen Y; Wu Y Cell Mol Neurobiol; 2021 Mar; 41(2):341-351. PubMed ID: 32335773 [TBL] [Abstract][Full Text] [Related]
8. Novel Function of lncRNA ADAMTS9-AS2 in Promoting Temozolomide Resistance in Glioblastoma via Upregulating the FUS/MDM2 Ubiquitination Axis. Yan Y; Xu Z; Chen X; Wang X; Zeng S; Zhao Z; Qian L; Li Z; Wei J; Huo L; Li X; Gong Z; Sun L Front Cell Dev Biol; 2019; 7():217. PubMed ID: 31632968 [TBL] [Abstract][Full Text] [Related]
9. TRIM22 inhibits the TRAF6-stimulated NF-κB pathway by targeting TAB2 for degradation. Qiu H; Huang F; Xiao H; Sun B; Yang R Virol Sin; 2013 Aug; 28(4):209-15. PubMed ID: 23818111 [TBL] [Abstract][Full Text] [Related]
10. Aberrant KAT2A accumulations render TRIM22-low melanoma sensitive to Notch1 inhibitors via epigenetic reprogramming. Gu X; Min W; Zeng Y; Fan N; Qian Q J Transl Med; 2023 Jul; 21(1):443. PubMed ID: 37415153 [TBL] [Abstract][Full Text] [Related]
11. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243 [TBL] [Abstract][Full Text] [Related]
12. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
13. TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosis. Zhang L; Zhang B; Wei M; Xu Z; Kong W; Deng K; Xu X; Zhang L; Ζhao X; Yan L Int J Oncol; 2020 May; 56(5):1225-1239. PubMed ID: 32319602 [TBL] [Abstract][Full Text] [Related]
14. Control of FoxO4 Activity and Cell Survival by TRIM22 Directs TLR3-Stimulated Cells Toward IFN Type I Gene Induction or Apoptosis. Oteiza A; Mechti N J Interferon Cytokine Res; 2015 Nov; 35(11):859-74. PubMed ID: 26237181 [TBL] [Abstract][Full Text] [Related]
15. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831 [TBL] [Abstract][Full Text] [Related]
16. TRIM22 can activate the noncanonical NF-κB pathway by affecting IKKα. Qiu H; Huang F; Gong J; Xiao H; Sun BL; Yang RG J Recept Signal Transduct Res; 2015; 35(4):289-94. PubMed ID: 25510414 [TBL] [Abstract][Full Text] [Related]
17. miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling. Tian H; He Z Yonsei Med J; 2018 Jun; 59(4):511-518. PubMed ID: 29749134 [TBL] [Abstract][Full Text] [Related]
18. NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells. Wang X; Jia L; Jin X; Liu Q; Cao W; Gao X; Yang M; Sun B Oncol Lett; 2015 Jun; 9(6):2586-2590. PubMed ID: 26137111 [TBL] [Abstract][Full Text] [Related]
19. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. Wang HH; Chang TY; Lin WC; Wei KC; Shin JW Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714 [TBL] [Abstract][Full Text] [Related]
20. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling. Liu W; Zhao Y; Wang G; Feng S; Ge X; Ye W; Wang Z; Zhu Y; Cai W; Bai J; Zhou X Redox Biol; 2022 Jul; 53():102344. PubMed ID: 35636015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]